PORTFOLIO NEWS ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update August 11, 2022 Read More » RAPT Therapeutics Reports Second Quarter 2022 Financial Results August 11, 2022 Read More » Surrozen Reports Second Quarter 2022 Financial Results August 11, 2022 Read More » Tenaya Therapeutics Reports Second Quarter 2022 Financial Results & Provides Business Update August 10, 2022 Read More » eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update August 9, 2022 Read More » eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer August 8, 2022 Read More » Kallyope’s Newly Established Clinical Development Advisory Board Joined By Renowned Biopharma Leaders August 5, 2022 Read More » NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results August 4, 2022 Read More » Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer August 3, 2022 Read More » Carmot Therapeutics Closes $160 Million Series D Financing to Advance Clinical Pipeline of Novel Incretin Receptor Modulators July 26, 2022 Read More » « Previous Page1 Page2 Page3 Page4 Page5 Page6 Page7 Page8 Page9 Page10 Page11 Page12 Page13 Page14 Page15 Page16 Page17 Page18 Page19 Page20 Next »
ORIC Pharmaceuticals Reports Second Quarter 2022 Financial Results and Operational Update August 11, 2022 Read More »
Tenaya Therapeutics Reports Second Quarter 2022 Financial Results & Provides Business Update August 10, 2022 Read More »
eFFECTOR Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update August 9, 2022 Read More »
eFFECTOR Therapeutics Appoints Douglas Warner, M.D., as Chief Medical Officer August 8, 2022 Read More »
Kallyope’s Newly Established Clinical Development Advisory Board Joined By Renowned Biopharma Leaders August 5, 2022 Read More »
NGM Bio Provides Business Highlights and Reports Second Quarter 2022 Financial Results August 4, 2022 Read More »
Nurix Therapeutics Announces Appointment of Eric Schlezinger, J.D. as Chief People Officer August 3, 2022 Read More »
Carmot Therapeutics Closes $160 Million Series D Financing to Advance Clinical Pipeline of Novel Incretin Receptor Modulators July 26, 2022 Read More »
